SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending amid discussions of its latest earnings call, with community members debating whether the results met expectations and what the implications are for future growth. Sentiment appears mixed, with some investors expressing concerns about profitability and Elon Musk's credibility, while others remain optimistic about Tesla's long-term potential and expansion into areas like robotics. The community is also focused on Tesla's valuation, future prospects, and the impact of ending EV incentives.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as community members discuss the CEO's comments regarding Phase 3 oral trials and potential M&A interest in their NASH assets. The enthusiasm is fueled by optimism for Viking's obesity and metabolic pipeline, with some drawing parallels to previous acquisitions in the biotech space. Community members are actively debating whether the stock is currently undervalued amidst short-term volatility.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following positive reports regarding its quantum computing capabilities and a partnership with HSBC to improve bond trading predictions, with some community members speculating this is the beginning of a larger upward trend.  The stock is experiencing increased attention and bullish sentiment, especially as it positions itself in the AI and quantum computing sectors. Some investors believe that IBM is undervalued, given its strong position in quantum computing and AI, and is a safer bet compared to pure-play quantum stocks.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors digest the latest earnings report and assess the company's progress towards commercialization. The community is focused on potential partnerships with automotive OEMs, especially following Elon Musk's comments on new battery tech, and the significance of customer billings. While some express concerns about the company's cash burn and lack of revenue, others remain optimistic about its long-term potential in the solid-state battery market.

Houston American Energy Corp. is an independent oil and gas company, which engages in the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. The firm holds interest in the Texas Permian Basin, the onshore Texas and Louisiana Gulf Coast region and in the South American country of Colombia. It operates through the North America and South America geographical segments. The company was founded on April 2, 2001 and is headquartered in Houston, TX.

Houston American Energy Corp

Houston American Energy ($HUSA) is trending as traders discuss its potential amid ongoing geopolitical tensions and fluctuations in oil prices. Community members are weighing the possibility of a short squeeze, while others cite concerns about dilution and past performance. The stock remains an active point of discussion among traders focused on energy and micro-cap plays.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community members discuss its potential as a sympathy play amid the recent surge in other meme stocks like $BYND, with some drawing parallels to the 2021 short squeeze and suggesting history could repeat itself. Discussions also involve the company's fundamentals, potential catalysts, and the influence of key figures, including Ryan Cohen. Some traders express frustration, while others remain optimistic about a potential breakout.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

LRCX is trending due to positive Q126 earnings results and forward guidance, sparking discussions around AI chip production and tariff impacts. Community members are actively debating the company's growth potential, particularly in relation to China's market and competition, with some eyeing specific price milestones while acknowledging potential risks.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings (SLMT) is trending due to a significant after-hours surge, reportedly fueled by news and a low float. The community is actively discussing the potential for a short squeeze and further upside, while also noting the stock's previous decline. Some investors are highlighting the company's connection to Solana and anticipating gains if the cryptocurrency rebounds.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

MOH is trending due to lowered annual profit forecasts, driven by unexpectedly high medical costs, particularly within its Obamacare Marketplace business, sparking discussion around cost spirals impacting health insurers. Community sentiment appears negative, with some anticipating further declines and comparing MOH unfavorably to competitors. The news has triggered broader concerns about the healthcare sector's financial health and potential impacts on premiums.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

Beasley Broadcast Group is trending as traders discuss its potential as the next low float runner, citing its small float and increasing volume. The community is watching for a breakout, with some eyeing a move towards a key moving average. Recent low float runners are also being referenced as potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a...

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug Administration granted Fast Track designation to its experimental treatment for alopecia areata.The drug, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody being tested in a Phase 2 trial for alopecia areata (AA), an autoimmune disorder that causes hair loss.&nbsp;The Fast Track status is intended to speed development of therapies that address serious conditions and unmet medical needs."The Fast Track designation granted by the FDA recognizes the seriousness of AA and the significant current unmet medical need while underscoring bempikibart's potential as a novel, differentiated therapy," said Q32 Bio Chief Executive Jodie Morrison in a statement.Bempikibart is designed to re-regulate immune function by blocking IL-7 and TSLP signaling pathways, key components in autoimmune activity.&nbsp;The company recently began dosing patients in both an open-label extension and Part B of its SIGNAL-AA trial following encouraging early results.The FDA designation allows for more frequent meetings with the agency, eligibility for priority review, and the possibility of accelerated approval, subject to clinical results.On Stocktwits, 24-hour message volume for Regulus jumped by 1,600% amid bullish sentiment.Some users highlighted the stock’s low float and recent FDA news as drivers for a potential swing trade, while others noted that the therapy itself — bempikibart — is making steady clinical progress.&nbsp;<stembedurl>https://stocktwits.com/onlyfactshere/message/613083538</stembedurl>One user pointed to the Fast Track status as a key catalyst, potentially accelerating development timelines for a treatment area with few approved options.&nbsp;<stembedurl>https://stocktwits.com/ALOSETE/message/613089756</stembedurl>Still, some cautioned that despite promising Phase 2 data, the company’s limited cash runway — estimated at about five quarters — underscores the inherent risks of biotech investing.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/613078123</stembedurl>Shares of Q32 Bio have declined 1.9% year-to-date, underperforming the Nasdaq, which is down 1.6%, but faring better than the Dow and S&amp;P 500, which have fallen 4.1% and 5.1%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.

Equity

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio to Participate in Upcoming March Investor Conferences Q32 Bio to Participate in Upcoming March Investor Conferences PR Newswire WALTHAM, Mass., Feb. 26, 2025 WALTHAM, Mass., Feb. 26, 2025...

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in...

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference PR Newswire WALTHAM...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of its lead candidate, bempikibart (ADX-914).&nbsp;The clinical-stage biotech company is under heavy selling pressure, with retail sentiment turning ‘extremely bearish’ on Stocktwits amid a spike in message volume.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QTTB_sentiment_and_message_volume_on_Dec_11_5dea79b168.png" alt="QTTB sentiment and message volume on Dec 11.png" width="1318" height="324"><figcaption>QTTB sentiment and message volume on Dec 11 as of 8:30 am ET | source: Stocktwits</figcaption></figure>The SIGNAL-AA trial for alopecia areata showed “encouraging” clinical activity, with a mean reduction of 16% in the Severity of Alopecia Tool (SALT) score for bempikibart recipients versus 2% in the placebo group at 24 weeks.&nbsp;However, only 9% of bempikibart patients achieved SALT-20, compared to none in the placebo group.Meanwhile, the SIGNAL-AD trial for atopic dermatitis failed to meet its primary endpoint in Part B, with patients receiving bempikibart showing a 74% improvement in the Eczema Area and Severity Index at 14 weeks, compared to 76% in the placebo group.&nbsp;CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better.The mixed results prompted a series of downgrades:• Wells Fargo cut its rating to ‘Equal Weight’ from ‘Overweight’ and slashed its price target to $16 from $95, citing disappointing atopic dermatitis results and concerns over Q32’s cash needs.• Leerink lowered its rating to ‘Market Perform’ from ‘Outperform’, with a price target of $9, down from $68. The firm removed atopic dermatitis value from its model and noted uncertainty around alopecia areata progression.• Raymond James downgraded Q32 Bio to ‘Outperform’ from ‘Strong Buy’, with its price target falling to $22 from $90. Analyst Steven Seedhouse highlighted underestimated market reaction but acknowledged the potential of the IL7R-4 mechanism.• Oppenheimer reduced its price target to $20 from $80 while maintaining an ‘Outperform’ rating, citing the alopecia opportunity’s potential despite setbacks in atopic dermatitis.Despite the sharp decline, QTTB shares remain up over 120% year-to-date.&nbsp;However, near-term sentiment and confidence in the stock have been severely dented, with investors awaiting further clarity on the drug’s development plans.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Q32 Bio Stock Plunges After Analyst Downgrades, Price-Target Slashes Over Alopecia Data: Retail Confidence Drops

CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing...

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov...

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 Q32 Bio to Present Tissue-Targeted...

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Aug. 29, 2024 WALTHAM, Mass., Aug. 29...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

QTTB
Q32 Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QTTB News

QTTBQ32 Bio Inc.